Temporal Changes in the Treatment Received in Patients Referring to TAVR

Conclusions: Despite newer TAVR devices and extended labeling, many patients are still excluded from having TAVR. FDA approval of TAVR resulted in overall in-crease of both TAVR and SAVR, while the number of patients treated with BAV of medical therapy continues to decline.

TCT-729
Four years durability of clinical and hemodynamic outcomes of transcatheter aortic valve implantation with self expanding CoreValve: A single center experience
Simona Galino1, Marco Barbanti2, Wanda Deste1, Stefano Innocenti1, Emanuele Benvenuto1, Letizia Santonoceto1, Dario Liberto1, Alessio Di Landro1, Patrizia Aruti1, Vera Bottari1, Rita Siccius1, Andrea Sole1, Claudia Tamburino1, Denise Todaro1, Emanuela Di Simone1, Carmelo Sgroi1, Corrado Tamburino1
Ferraro Rita Hospital. University of Catania, Catania, Italy

Background: Although Transcatheter Aortic Valve Implantation (TAVI) has confirmed itself as a promising technique guaranteeing similar results to surgical aortic valve replacement (SAVR), long-term data on valve function and clinical outcomes are limited. We sought to assess 4-year clinical and echocardiographic outcomes in patients undergoing Transcatheter Aortic Valve Implantation (TAVI) with CoreValve prosthesis.

Methods: Between June 2007 and February 2014, 450 consecutive patients with symptomatic severe aortic stenosis underwent TAVI using both CoreValve, Edwards-SAPIEN, and Lotus valves. For the purposes of this study we included only those patients undergoing successful TAVI with CoreValve prosthesis who had a minimum follow-up of 4 years (n=125). All outcomes were defined according to the Valve Academic Research Consortium (VARC 2).

Results: Survival at 1, 2, 3 and 4 years were 83.2, 76.8, 73.6 and 66.3%, respectively. Survival from cardiovascular mortality rates at 1, 2, 3 and 4 years were 88.0, 84.0, 83.2 and 80.8%, respectively. No deaths were directly related to valvular dysfunction. Freedom from reoperation was 98.5%. We reported satisfactory long-term valve performance in terms of mean pressure gradients and aortic valve area (AVA). Echocardiographic follow-up revealed a mean pressure gradients decreasing from 57±17.4 mmHg (pre-TAVI) to 10.4±4.5 mmHg (post-TAVI) (P<0.001) with a small increase at 1 year (12.48±6.8 mmHg), which remained steady at 4 years (11.9±7.1 mmHg). In the majority of cases mild paravalvular regurgitation (PVR) were either unchanged or slightly improved overtime. Progression from mild acute PVR to moderate PVR at 4-year follow-up was reported in three patients. Prosthetic valve failure was reported in 4 patients (3.2%). Valve thrombosis or late valve embolization were not reported.

Conclusions: Our study demonstrated that favorable outcomes after successful TAVI are associated with sustained clinical and functional cardiovascular benefits up to 4-year follow-up. Signs of moderate prosthetic valve failure are present only in a small percentage of patients.

TCT-730
Long-term performance of a transfemorally implantable nonmetallic, retrievable and repositionalable aortic valve in patients with severe aortic stenosis: 5 Year Follow-Up of the 22 F Direct Flow Medical Valve
Klaudia Bielik1, Hendrik Treede2, Hermann Reichenspurner2, Eberhard Grube2, Joachim Schofer1
1Medical Care Center Prof Mathy Prof Schofer, Hamburg, Germany, 2Hamburg University, Hamburg, Germany

Conclusions: Despite new TAVR devices and extended labeling, many patients are still excluded from having TAVR. FDA approval of TAVR resulted in overall increase of both TAVR and SAVR, while the number of patients treated with BAV of medical therapy continues to decline.

TCT-731
Reasons for Hospital Readmission Within One Year After Transcatheter Aortic Valve Implantation
Stefan Sorecky1, Nicolas Arnold1, Dirk Heg1, Croghan J. O’Sullivan1, Thomas Pilgrim1, Ahmed Khattab1, Lutz Buellesfeld1, Peter Wenaweser1, Stephan Windescher1
1Bern University Hospital, Bern, Switzerland, 2Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland

Background: Elderly patients with severe aortic stenosis and numerous cardiac and non-cardiac comorbidities are currently considered for transcatheter aortic valve implantation (TAVI). TAVI is effective in alleviating valve-related symptoms and restoring quality of life. However, many patients remain frail and in a vulnerable clinical condition after successful TAVI. The aim of this study was to assess rates and reasons for rehospitalization within one year after TAVI.

Methods: Between August 2007 and September 2012, 549 consecutive patients with degenerative aortic stenosis underwent TAVI using different access routes and devices and were included into a prospective registry. Active follow-up was scheduled at 30 days, 6 months and 1 year. All hospital readmissions were ascertained and major adverse events were adjudicated according to the VARC2 standardized endpoint definitions.

Results: Of 549 patients undergoing TAVI, 529(96.4%) were alive at the end of the index hospitalization and discharged. Of these, 138(26.1%) patients were readmitted within 1 year of discharge and included in the present analysis. Patients with at least one readmission had presented with higher logistic EuroScore (25.1±16 vs. 22.1±13 mmHg; p<0.01), higher systolic pulmonary artery pressure (55.5±19 vs. 50.2±16 mmHg; p=0.02), lower left ventricular ejection fraction (49.0±16 vs. 53.3±14 mmHg; p=0.009) and more frequently had previous myocardial infarction (21.7% vs. 13%; p<0.02). Overall, 176 readmissions occurred during the observational period with a cumulative mean hospital duration of 15.6±16 days. Among readmitted patients, 73 patients(41.5%) were re-evaluated for cardiovascular causes (heart failure 17%, peripheral vascular disease 15%, 2% for valvular heart disease), 22 (13%) for gastrointestinal, 12 (7%) for respiratory and 8 patients (5%) for chronic kidney disease. Twenty-two patients (13%) received non-cardiac surgery and 8 patients (5%) were found to have a malignant tumor.

Conclusions: Within the first year after TAVI, one out of four patients is readmitted to the hospital. Cardiac causes and vascular disease are among the most frequent reasons for rehospitalization, while readmission for valve related issues is rare.

TCT-732
Prognostic Value Of Impaired Left Ventricular Function In Patients Undergoing Transapical Versus Transfemoral Transcatheter Aortic Valve Implantation (TAVI)
Vincent J. Nijenhuis1, Robien Heijmen1, Martin Swaans2, Thomas de Kroon3, Jan Van der Heyden4, Jurrien M. Ten Berg5
1St Antonius hospital, Nieuwegein, Netherlands, 2St Antonius Hospital, Nieuwegein, Netherlands, 3St. Antonius Hospital, Nieuwegein , Netherlands, 4N/A, Nieuwegein, Netherlands, 5St. Antonius Hospital, Nieuwegein, Netherlands

Background: An impaired left ventricular ejection fraction (LVEF) severely affects prognosis and peri-operative risk in patients undergoing surgical aortic valve replacement. Also in patients undergoing TAVI, an impaired LVEF seems to affect prognosis, although contradictory findings exist. We analyzed the effects of an